These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 3519886

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prospective sequential trials of induction weekly cisplatin followed by monthly cisplatin, doxorubicin, cyclophosphamide and paclitaxel and cisplatin in optimal (< or = 1 cm) stage III and IV ovarian cancer.
    Piver MS, Eltabbakh GH, Hempling RE, Recio FO, Blumenson LE.
    Eur J Gynaecol Oncol; 1998; 19(1):5-10. PubMed ID: 9476049
    [Abstract] [Full Text] [Related]

  • 9. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S, Yeap B, Vogl S, Carbone P.
    Cancer; 1996 Feb 15; 77(4):733-42. PubMed ID: 8616766
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ, Lele SB.
    Cancer Treat Rep; 1984 Dec 15; 68(12):1433-8. PubMed ID: 6439408
    [Abstract] [Full Text] [Related]

  • 13. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [Abstract] [Full Text] [Related]

  • 14. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
    Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R.
    J Clin Oncol; 1989 Apr 15; 7(4):457-65. PubMed ID: 2926470
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial.
    Williams CJ, Mead GM, Macbeth FR, Thompson J, Whitehouse JM, MacDonald H, Harvey VJ, Slevin ML, Lister TA, Shepherd JH.
    J Clin Oncol; 1985 Nov 15; 3(11):1455-62. PubMed ID: 3903062
    [Abstract] [Full Text] [Related]

  • 17. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer.
    Mouratidou D, Gennatas C, Michalaki V, Papadimitriou A, Andreadis CH, Sykiotis C, Tsavaris N.
    Anticancer Res; 2007 Nov 15; 27(1B):681-5. PubMed ID: 17348460
    [Abstract] [Full Text] [Related]

  • 18. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
    Grem J, O'Dwyer P, Elson P, Simon N, Trump D, Frontiera M, Falkson G, Vogl S.
    J Clin Oncol; 1991 Oct 15; 9(10):1793-800. PubMed ID: 1919629
    [Abstract] [Full Text] [Related]

  • 19. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
    Potamianou A, Androulakis N, Papakotoulas P, Toufexi H, Latoufis C, Kouroussis C, Christofilakis C, Xenidis N, Georgoulias V, Polyzos A.
    Oncology; 2005 Oct 15; 69(4):348-53. PubMed ID: 16293974
    [Abstract] [Full Text] [Related]

  • 20. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer.
    Bolis G, Favalli G, Danese S, Zanaboni F, Mangili G, Scarabelli C, Tateo S, Valsecchi MG, Scarfone G, Richiardi G, Frigerio L, Melpignano M, Villa A, Parazzini F.
    J Clin Oncol; 1997 May 15; 15(5):1938-44. PubMed ID: 9164205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.